These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 2963053)

  • 41. Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine.
    Wells BG; Evans RL; Ereshefsky L; Antal EJ; Lobeck F; Rawls WN; Hamann G; Grimmig J; Smith RB
    J Clin Psychiatry; 1988 Oct; 49(10):394-9. PubMed ID: 3049560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
    Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
    Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptom comorbidity in anxiety and depressive disorders.
    Copp JE; Schwiderski UE; Robinson DS
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):52S-60S. PubMed ID: 1973940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A psychometric reanalysis of the Albany Panic and Phobia Questionnaire.
    Brown TA; White KS; Barlow DH
    Behav Res Ther; 2005 Mar; 43(3):337-55. PubMed ID: 15680930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of panic disorder with imipramine alone.
    Garakani H; Zitrin CM; Klein DF
    Am J Psychiatry; 1984 Mar; 141(3):446-8. PubMed ID: 6367495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidepressant specificity in atypical depression.
    Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
    Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients.
    Lôo H; Malka R; Defrance R; Barrucand D; Benard JY; Niox-Rivière H; Raab A; Sarda A; Vachonfrance G; Kamoun A
    Neuropsychobiology; 1988; 19(2):79-85. PubMed ID: 3067116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
    Zajecka JM
    J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in the drug treatment of anxiety disorders.
    Pohl R; Rainey JM; Gershon S
    Psychopathology; 1984; 17 Suppl 1():6-14. PubMed ID: 6369369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1989 Feb; 46(2):127-31. PubMed ID: 2643933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.
    Jonas JM; Cohon MS
    J Clin Psychiatry; 1993 Oct; 54 Suppl():25-45; discussion 46-8. PubMed ID: 8262888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The influence of alprazolam on the symptoms of anxiety and depression].
    Małyszczak K; Kiejna A
    Psychiatr Pol; 1997; 31(6):745-52. PubMed ID: 9515306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving depression severity assessment--II. Content, concurrent and external validity of three observer depression scales.
    Maier W; Heuser I; Philipp M; Frommberger U; Demuth W
    J Psychiatr Res; 1988; 22(1):13-9. PubMed ID: 3397905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
    Başoğlu M; Marks IM; Kiliç C; Swinson RP; Noshirvani H; Kuch K; O'Sullivan G
    Br J Psychiatry; 1994 May; 164(5):647-52. PubMed ID: 7921715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alprazolam compared to amitriptyline in the treatment of major depression.
    Eriksson B; Nagy A; Starmark JE; Thelander U
    Acta Psychiatr Scand; 1987 Jun; 75(6):656-63. PubMed ID: 3618289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind comparison of alprazolam vs. imipramine and placebo in the treatment of major depressive disorder.
    Feighner JP; Meredith CH; Frost NR; Chammas S; Hendrickson G
    Acta Psychiatr Scand; 1983 Oct; 68(4):223-33. PubMed ID: 6138925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trait anxiety and defensive functioning in relation to antidepressant treatment outcome.
    Sukul YR; Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA
    Psychopathology; 2009; 42(6):387-93. PubMed ID: 19776669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An overview of which health domains to consider and when to apply them in measurement-based care for depression and anxiety disorders.
    Bech P; Timmerby N
    Nord J Psychiatry; 2018 Jul; 72(5):367-373. PubMed ID: 29714082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.